Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Detroit mayor turned down J&J vaccine in favor of others

03/05/2021 | 04:23pm EDT

LANSING, Mich. (AP) — Detroit this week turned down 6,200 doses of the newly authorized Johnson & Johnson coronavirus vaccine, favoring shots from Pfizer and Moderna, but said Friday it will accept J&J doses in the state's next allocation.

Mayor Mike Duggan had said Thursday that residents should get the “best” vaccines — from Moderna and Pfizer — conflicting with guidance from top state and federal health officials who caution against comparing the three vaccines and note all provide strong protection against the worst outcomes.

Duggan had also said the allotment of 29,000 Pfizer and Moderna doses “covered everyone who wanted a vaccination this week." On Friday, he called J&J vaccines "a key part of our expansion of vaccine centers.”

No other local health department declined any of the 82,700 J&J shots sent to Michigan this week, the state health department said.

Dr. Joneigh Khaldun, Michigan's chief medical executive, said earlier in the week that people who are offered the J&J vaccine should "take it because declining ... could be the difference between life and death.” In a statement Friday, she cited differences in when and where each company conducted its studies, with the Moderna and Pfizer research finished before concerning variants began spreading.

In the U.S., the two-dose Pfizer and Moderna shots were 95% protective against symptomatic COVID-19. J&J’s one-dose effectiveness of 85% against severe COVID-19 dropped to 66% when moderate cases were rolled in. The Food and Drug Administration has reported that, just like its predecessors, the J&J shot strongly safeguards against serious illness, hospitalization and death.

“All of the vaccines are safe and effective and I recommend that all vaccines be offered in all communities,” Khaldun said.

White House coronavirus special adviser Andy Slavitt said Friday that the White House talked to the Detroit mayor's office, which called the situation a “misunderstanding.”

“In fact, he is very eager for the Johnson & Johnson vaccine,” Slavitt said of Duggan.

As of Wednesday, 11% of Detroit residents age 16 and older had gotten at least one dose. The statewide rate was 19%.

Detroit this week expanded vaccinations to any resident who is a factory worker, no matter their age or where they work. Non-residents can also get a shot if they work in manufacturing in the city.

Detroit's 6,200 J&J doses went to health departments in counties with the lowest vaccination rates of people age 65 and up, state spokesman Bob Wheaton said.

J&J's vaccine is produced using a cell line derived from an aborted fetus, which has prompted moral concerns from Catholic leaders. The chairmen of the United States Conference of Catholic Bishops’ committees on doctrine and abortion issues said the Pfizer or Moderna vaccines are preferable “if one has the ability to choose a vaccine.”

A $4.2 billion COVID-19 relief plan approved by Michigan's Republican-led Legislature this week includes a provision that would require vaccine recipients to be informed if and in what manner their vaccine was developed with aborted fetal tissue or human embryonic stem cells. Democratic Gov. Gretchen Whitmer could declare the item unenforceable.

Associated Press writer Zeke Miller in Washington contributed to this report.

Follow David Eggert at https://twitter.com/DavidEggert00

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.28% 162.69 Delayed Quote.3.37%
MODERNA, INC. -5.21% 161.91 Delayed Quote.63.50%
PFIZER, INC. 0.93% 38.93 Delayed Quote.4.78%
All news about PFIZER, INC.
04/19JOHNSON & PHILLIPS PAKISTAN  : India to waive import duty on COVID-19 vaccines, ..
04/19THE LATEST : Permit denied for Dutch festival, test event
04/19PFIZER  : Germany expects vaccine deliveries to ramp up in 2nd quarter
04/19Pfizer Up Eighth Consecutive Day, On Track for Longest Winning Streak Since J..
04/19ASTRAZENECA  : J&J COVID-19 vaccine reviewed for links to additional reports of ..
04/19ANKYLOSING SPONDYLITIS PIPELINE : Emerging Therapies and Key pharma players invo..
04/19South Africa's vaccine compensation fund could cost $17.5 mln in first year
04/19WALL STREET STOCK EXCHANGE : New York opens lower
04/19PFIZER  : EU to Order Additional 100 Million Doses of Pfizer, BioNTech's COVID-1..
04/19BIONTECH  : Pfizer, BioNTech to Deliver Extra 100 Million COVID-19 Doses in the ..
More news
Financials (USD)
Sales 2021 60 621 M - -
Net income 2021 16 304 M - -
Net Debt 2021 28 901 M - -
P/E ratio 2021 14,5x
Yield 2021 4,02%
Capitalization 217 B 217 B -
EV / Sales 2021 4,06x
EV / Sales 2022 4,53x
Nbr of Employees 78 500
Free-Float 59,0%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 24
Average target price 40,64 $
Last Close Price 38,93 $
Spread / Highest target 36,1%
Spread / Average Target 4,39%
Spread / Lowest Target -7,53%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER, INC.4.78%215 150
JOHNSON & JOHNSON3.37%427 130
ROCHE HOLDING AG0.06%289 376
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.06%196 100
ABBVIE INC.1.36%190 442